123 related articles for article (PubMed ID: 14681960)
1. [Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Gusev EI; Martynov MIu; Boĭko AN; Petukhov EB; Makarov AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):15-20. PubMed ID: 14681960
[TBL] [Abstract][Full Text] [Related]
2. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
Ametov AS; Demidova TIu; Kosykh SA
Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
[TBL] [Abstract][Full Text] [Related]
3. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
[TBL] [Abstract][Full Text] [Related]
4. [Eprosartan mesylate in controlling of blood pressure in patients with ischemic stroke].
Martynov MIu; Boĭko AN; Petukhov EB; Berezov VP; Maskarov AN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(4):26-30. PubMed ID: 12001661
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
6. [Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests].
Shevchenko OP; Praskurnichiĭ EA; Makarova SV; Samartsev GA; Lapina EIa
Kardiologiia; 2004; 44(3):58-63. PubMed ID: 15489829
[No Abstract] [Full Text] [Related]
7. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A; Verboom CN; Jäger B
J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
[TBL] [Abstract][Full Text] [Related]
8. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
9. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA; Punzi CF
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Dowlatshahi D; Hill MD
Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
[TBL] [Abstract][Full Text] [Related]
13. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
14. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg NK
Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone FC; Coatney RW; Chandra S; Sarkar SK; Nelson AH; Contino LC; Brooks DP; Campbell WG; Ohlstein EH; Willette RN
Cardiovasc Res; 2001 Jun; 50(3):525-37. PubMed ID: 11376628
[TBL] [Abstract][Full Text] [Related]
16. Eprosartan for the treatment of hypertension.
Ruilope L; Jäger B
Expert Opin Pharmacother; 2003 Jan; 4(1):107-14. PubMed ID: 12517247
[TBL] [Abstract][Full Text] [Related]
17. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
18. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability].
Shalaev SV; Metlitskaia EV; Teffenberg DV; Shanaurina NV; Petrik ES; Volkova SIu
Kardiologiia; 2004; 44(1):10-3. PubMed ID: 15029143
[TBL] [Abstract][Full Text] [Related]
20. [Effect of eprosartan on left ventricular diastolic function and cerebral hemodynamics in patients with hypertension].
Markova LI; Radzevich AE; Koren'kov VV; Belavina NI; Griabina NA; Zharova OIu
Kardiologiia; 2002; 42(10):41-4. PubMed ID: 12494056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
